Reuters logo
BRIEF-Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017
September 26, 2017 / 12:28 PM / 24 days ago

BRIEF-Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017

Sept 26 (Reuters) - Catalyst Biosciences Inc

* Catalyst Biosciences granted FDA orphan drug designation for subcutaneous recombinant human Factor IX variant for treatment of hemophilia B

* Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017 and complete trial results in early 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below